This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share. ” The number of contracting facilities in India is smaller than in the US, but the industry there is growing rapidly.
Forge Biologics and global lifesciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration.
At the DIA 2024 Global Annual Meeting, Phastar iwill be proud to join a diverse group of stakeholders from industry, regulatory bodies, academia, and patient communities.
The Healthcare Businesswoman’s Association Europe region released an update to its 2018 industry gender pay gap report that shows there is a clear increase in the pay gap between men and women in the lifesciences sector in Europe. France and the U.K. reduced the pay gap to 4.8 percent and 5.1 France and the U.K. percent and 5.1
To fully reap the benefits of tech advances, a company leader advises, a life-sciences firm must embrace change and connection throughout the operation.
Merck KGaA’s forecast for a tough 2023 is coming true, as the Darmstadt, Germany-based company’s contractmanufacturing division took a major hit from production timing and COVID-related sales down | Merck KGaA’s lifescience services business unit, which offers contractmanufacturing and contract testing services, logged a “strong organic sales decline” (..)
PWC predicts deal volumes to resemble prior years with the effect of the US Inflation Reduction Act on pricing better understood and less uncertainty surrounding business conditions, according to an article entitled Pharmaceutical & LifeSciences: US Deals 2023 Outlook published on the company’s website.
Manufacturer for the pharma and lifesciences industry, Gerresheimer, is investing more than $88 million to expand its operations in Peachtree City, Georgia.
Today, world-leading generative artificial intelligence (AI) company for lifesciences, Yseop, is celebrating its involvement in more than 150 clinical trials with pharma giants around the world.
Biocair has expanded its pharmaceutical and clinical trial logistics operations with new location in California, near Los Angeles International Airport.
Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada LifeScience business of Merck KGaA.
“Generally speaking, the overall environment has been a little bit more volatile for dealmaking, and you’ve seen that not just in corporate venture capital,” says Subin Baral, Ernst & Young’s Global Deals Leader for LifeSciences. However, among the deals included in this analysis, some themes have continued to stay constant.
The Bespoke Gene Therapy Consortium has more than $97 million in financial and in-kind commitments through partnerships with 33 member organizations that include 11 NIH institutes and centers, 12 lifescience companies and ten nonprofit organizations.
Manufacturer for the pharma and lifesciences industry, Gerresheimer, is investing more than $88 million to expand its operations in Peachtree City, Georgia.
The companyâs Azzur Cleanrooms on Demand division has established another facility in Vista, a city in the San Diego Area, for life-sciences operations.
To achieve this outcome, lifesciences service provider Cytiva designed the Global Biopharma Resilience Index to serve as a health-check on the resilience, adaptability, and preparedness of the industry. All of a sudden, the industry understood the critical importance of identifying its pain points and how they can be alleviated.
Clinical Services International is a trusted partner of leading pharmaceutical and biotechnology companies, contract research organisations, and contractmanufacturing organisations. It makes sense then to partner with an expert in sourcing to ensure the most efficient, risk-free, and cost-effective solution possible.
According to the company, $715 million of the investment will go towards expanding Lonza’s existing Visp facility where Lonza aims to increase large-scale biologics manufacturing capacity to meet customer demand in the contractmanufacturing space.
As a result, many small drug developers and occasionally larger pharmaceutical companies prefer to outsource manufacturing to contract service providers. The growing demand for firms offering manufacturing and sometimes development services has led to the emergence of numerous contractmanufacturing organizations.
6, 2021 /PRNewswire/ — The lifescience company Sartorius today announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep.
Proposed transaction builds on both companies’ strategic R&D partnership.
Veeva is the global leader in cloud software for the lifesciences industry. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical ContractManufacturing. About Veeva Systems. Source link: [link].
Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant LifeSciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and ContractManufacturing of Sterile (..)
While we are deliberately sector generalists, some of our primary interest areas include Medical Products, Industrial Technology, LifeSciences, Aerospace & Defense, and Specialty Materials. We approach investments from multiple perspectives but share a single vision – to identify and unlock the breakout potential in our companies.
“In response to increased demand for early phase therapeutic and diagnostic development services, SpectronRx has experienced significant growth as an early-stage contract developer for global and domestic lifesciences companies,” added Anwer Rizvi, President of SpectronRx.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical ContractManufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical ContractManufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros.
This venture also led me to identify a gap in the market for contractmanufacturing of recombinant proteins. Together, we developed the world’s first growth hormone receptor antagonist, Somavert (pegvisomant), targeting acromegaly.
Apart from its own contractedmanufacturing facilities, unexpected production help has been coming in from rival drug-makers including Sanofi, Bayer and Novartis who are pitching in to produce millions more doses of BNT162b. BioNTech is also launching a factory upgrade in Puurs, Belgium.
The company expects the average manufacturing turnaround time to be 34 days, which is from when a tumor sample reaches the manufacturing facility to final release of the product, but without taking into account delivery times.
In last month’s call, Legend CEO Ying Huang, PhD, shared that the partners are aiming to increase manufacturing capacity at their New Jersey plant. In addition, the companies are also gunning for a first-line setting approval.
As a bioscience accelerator at the leading-edge of the lifescience industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. .
VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp.
She chairs the board of directors of Sellas LifeSciences, a publicly traded biotechnology company, chairs its nominations & governance committee, and is a member of its audit, compensation and finance committees. and international leadership positions, including Staff Vice President and Associate General Counsel.
INOVIO is also assessing nonclinical efficacy of INO-4800 in several animal challenge models with Public Health England (PHE) and Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia.
But it remains to be seen how Moderna will achieve the goal of producing more doses as it hasn’t announced any new partnerships with contractmanufacturers for increasing production of the vaccine. Moderna said it would be easier for the company to produce the vaccines themselves.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content